The EPS miss may weigh on shares near term. Focus on CASGEVY patient initiation momentum (64 patients infused in 2025) and upcoming pipeline catalysts in H2 2026 (zugo-cel data, CTX310/340 trial starts). The strong balance sheet supports the pipeline but does not erase the earnings disappointment.
Price Chart
Executive Summary
CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total revenue of $1.5M was up 69% YoY but still minimal. Net loss narrowed to $122.9M from $136.0M a year ago. CASGEVY generated $43M in global revenue (100% to Vertex; CRISPR's 40% share is netted in collaboration expense). No formal guidance was provided.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$1.28 vs consensus -$1.14 (12.3% miss)
- Total revenue: $1.5M (up 69% YoY from $0.9M)
- Net loss: -$122.9M vs -$136.0M in Q1 2025 (improved 9.6%)
- CASGEVY global revenue: $43M; 40% profit share to CRISPR (netted in collaboration expense)
- Cash & marketable securities: $2.44B (up from $1.98B at Dec 2025, boosted by $585M convertible note issuance)
- Pipeline progress: multiple Phase 1/2 trials advancing; FDA cleared IND for zugo-cel in autoimmune neurology
Financial Impact
EPS miss of $0.14 per share vs consensus; quarterly net cash burn ~$122.9M
Risk Factors
- Continued high R&D spend without near-term profitability
- Dependence on Vertex for CASGEVY commercialization
- Clinical trial risks across multiple early-stage programs
- Potential dilution from convertible notes (if converted)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204147 |
| Document: crsp-20260504.htm | 0001193125-26-204147 |
| Document: 0001193125-26-204147-index-headers.html | 0001193125-26-204147 |
| Document: 0001193125-26-204147-index.html | 0001193125-26-204147 |
| Document: 0001193125-26-204147.txt | 0001193125-26-204147 |
| 8-K Data (Synthetic) | 0001193125-26-204147 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $51.47 (−1.92%) |
Oct 19, 2026 8d ago | 8-K | $49.88 | awaiting T+20 | — | $51.47 (+3.19%) |
Oct 16, 2026 11d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $51.47 (+2.86%) |
Oct 16, 2026 11d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $51.47 (−2.86%) |
Oct 15, 2026 12d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $51.47 (+4.51%) |
Oct 14, 2026 13d ago | 144 | $51.52 | awaiting T+20 | — | $51.47 (−0.10%) |
Oct 6, 2026 21d ago | 144 | $52.35 | awaiting T+20 | — | $51.47 (−1.68%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $51.47 (+5.09%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $51.47 (−10.83%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $51.47 (−3.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers